Advertisement

International Journal of Clinical Oncology

, Volume 16, Issue 3, pp 221–229 | Cite as

Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma

  • Kazuhiro Kasai
  • Akira Ushio
  • Yukiho Kasai
  • Kei Sawara
  • Yasuhiro Miyamoto
  • Kanta Oikawa
  • Hidekatsu Kuroda
  • Yasuhiro Takikawa
  • Kazuyuki Suzuki
Original Article

Abstract

Background

This study evaluated the efficacy of combined 5-fluorouracil (5-FU) and pegylated interferon (PEG-IFN) α-2b in patients with advanced hepatocellular carcinoma (HCC).

Methods

Fifty patients with portal vein tumor thrombosis were enrolled. Of these, 21 patients were treated using subcutaneous administration of PEG-IFNα-2b and intra-arterial infusion of 5-FU (5-FU/PEG-IFN group), 12 patients were treated using intramuscular administration of IFNα-2b and intra-arterial infusion of 5-FU (5-FU/IFN group), and 17 patients received intra-arterial infusion chemotherapy with lipiodol-cisplatin (CDDP) suspension (CDDP group).

Results

The objective early response rate was significantly higher in the 5-FU/PEG-IFN group than in the 5-FU/IFN or CDDP groups (71.4 vs. 8.3% and 17.6%, respectively; P < 0.0001). Cumulative survival rates at 6 and 12 months were 83.8 and 77.8% in the 5-FU/PEG-IFN group, 60.8 and 16.2% in the 5-FU/IFN group, and 58.4 and 12.5% in the CDDP group, respectively. The cumulative survival rate was significantly higher in the 5-FU/PEG-IFN group than in the other 2 groups (P = 0.0272). Serious complications and treatment-related deaths were not observed in any of the 3 groups.

Conclusion

Although a prospective randomized controlled trial using a larger population of patients with advanced HCC is needed to evaluate combination therapy with 5-FU and PEG-IFNα-2b, this new combination therapy may be useful for patients with advanced HCC.

Keywords

5-Fluorouracil Hepatocellular carcinoma PEG-IFNα-2b Portal venous invasion 

Notes

Acknowledgment

The authors wish to thank Ms. Kouko Motodate for preparing serum samples.

Conflict of interest

No author has any conflict of interest.

References

  1. 1.
    EI-Serag HB, Mason A (1999) Rising incidence of hepatocellular carcinoma in United States. N Engl J Med 340:745–750CrossRefGoogle Scholar
  2. 2.
    Okuda K, Fujimoto I, Hanai A et al (1987) Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 47:4967–4972PubMedGoogle Scholar
  3. 3.
    La Vecchia C, Lucchini F, Franceschi S et al (2000) Trends in mortality from primary liver cancer in Europe. Eur J Cancer 36:909–915PubMedCrossRefGoogle Scholar
  4. 4.
    Ohtomo K, Furui S, Kokubo T et al (1985) Transcatheter arterial embolization (TAE) in treatment for hepatoma-analysis of three-year survivors. Radiat Med 3:176–180PubMedGoogle Scholar
  5. 5.
    Shiina S, Tagawa K, Unuma T et al (1990) Percutaneous ethanol injection therapy for treatment of hepatocellular carcinoma. Am J Roentgenol 154:947–951Google Scholar
  6. 6.
    Shiina S, Teratani T, Obi S et al (2002) Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 62(Suppl 1):64–68 (Review)PubMedCrossRefGoogle Scholar
  7. 7.
    Stehlin JS Jr, de Ipolyi PD, Greeff PJ et al (1988) Treatment of cancer of the liver: twenty years’ experience with infusion and resection in 414 patients. Ann Surg 208:23–35PubMedCrossRefGoogle Scholar
  8. 8.
    Ono Y, Yoshimasu T, Ashikaga R et al (2000) Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23:564–568PubMedGoogle Scholar
  9. 9.
    Yoshikawa M, Ono N, Yodono H et al (2008) Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38:474–483PubMedCrossRefGoogle Scholar
  10. 10.
    Sakon M, Nagano H, Dono K et al (2002) Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94:435–442PubMedCrossRefGoogle Scholar
  11. 11.
    Obi S, Yoshida H, Toune R et al (2006) Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106:1990–1997PubMedCrossRefGoogle Scholar
  12. 12.
    Glue P, Fang JW, Rouzier-Panis R et al (2000) Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 68:556–567PubMedCrossRefGoogle Scholar
  13. 13.
    Kasai K, Kuroda H, Ushio A et al (2009) Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. Hepatol Res 39:117–125PubMedCrossRefGoogle Scholar
  14. 14.
    Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRefGoogle Scholar
  15. 15.
    Liver Cancer Study Group of Japan (2000) The general rules for the clinical and pathological study of primary liver cancer, 4th edn. Kanehara, Tokyo, p 19 (in Japanese)Google Scholar
  16. 16.
    Irie T (2001) Intraarterial chemotherapy of liver metastasis: implantation of microcatheter-port system with use of modified fixed catheter tip technique. J Vasc Interv Radiol 12:1215–1218PubMedCrossRefGoogle Scholar
  17. 17.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  18. 18.
    NCI Common Toxicity Criteria. Common terminology criteria for adverse events v3.0 (CTCAE). Cited 9 August 2006. Available from: http://ctep.cancer.gov/reporting/ctc.html
  19. 19.
    Fujii T, Takayasu K, Muramatsu Y et al (1993) Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 23:105–109PubMedGoogle Scholar
  20. 20.
    Chen SC, Hsieh MY, Chuang WL et al (1994) Development of portal vein invasion and its outcome in hepatocellular carcinoma treated by transcatheter arterial chemo-embolization. J Gastroenterol Hepatol 9:1–6PubMedCrossRefGoogle Scholar
  21. 21.
    Schwartz EL, Hoffman M, O’Connor CJ et al (1992) Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun 182:1232–1239PubMedCrossRefGoogle Scholar
  22. 22.
    Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50:3473–3486PubMedGoogle Scholar
  23. 23.
    Elias L, Sandoval JM (1989) Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163:867–874PubMedCrossRefGoogle Scholar
  24. 24.
    Kondo M, Nagano H, Wada H et al (2005) Combination of IFN-α and 5-fluorouracil induces apoptosis through IFN-α/β receptor in human hepatocellular carcinoma cells. Clin Cancer Res 11:1277–1286PubMedCrossRefGoogle Scholar
  25. 25.
    Yano H, Iemura A, Haramaki M et al (1999) Interferon alfa receptor expression and growth inhibition by interferon alpha in human liver cell lines. Hepatology 29:1708–1717PubMedCrossRefGoogle Scholar
  26. 26.
    Silva M, Poo J, Wagner F et al (2006) A randomized trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 45:204–213PubMedCrossRefGoogle Scholar
  27. 27.
    Drewinko B, Yang L-Y (1985) Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Res 69:1391–1398Google Scholar
  28. 28.
    Guchelaar HJ, Vermes I, Koopmans RP et al (1998) Apoptosis-and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol 42:77–83PubMedCrossRefGoogle Scholar
  29. 29.
    Ueshima K, Tatsumi C, Sakaguchi Y et al (2006) Breakthrough of the hepatic arterial infusion chemotherapy of hepatocellular carcinoma. Gastroenterology (Tokyo) 43:253–259 (in Japanese)Google Scholar
  30. 30.
    Okada S, Okazaki N, Nose H et al (1992) Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology 16:112–117PubMedCrossRefGoogle Scholar
  31. 31.
    Uka K, Aikata H, Takaki S et al (2007) Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 42:845–853PubMedCrossRefGoogle Scholar
  32. 32.
    Kantoh T, Abo H, Tomotsu K et al (1993) Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization (TAE)––significance of repetitive therapies and responses to them within 6 months after the first intervention. Nippon Shokakibyo Gakkai Zasshi 90:1416–1424 (in Japanese)PubMedGoogle Scholar
  33. 33.
    Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2010

Authors and Affiliations

  • Kazuhiro Kasai
    • 1
  • Akira Ushio
    • 1
  • Yukiho Kasai
    • 1
  • Kei Sawara
    • 1
  • Yasuhiro Miyamoto
    • 1
  • Kanta Oikawa
    • 1
  • Hidekatsu Kuroda
    • 1
  • Yasuhiro Takikawa
    • 1
  • Kazuyuki Suzuki
    • 1
  1. 1.Division of Gastroenterology and Hepatology, Department of Internal MedicineIwate Medical UniversityMoriokaJapan

Personalised recommendations